
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 3 June 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a co-promotion agreement in the United States with Berlin-based Eckert & Ziegler Strahlen und Medizintechnik AG (EZAG) for the combination of EZAG's GalliaPharm[®] (gallium-68 generator) and Telix's investigational prostate cancer imaging product Illuccix[®] (Kit for the preparation of ⁶⁸Ga-PSMA-11 injection).

Under the terms of the agreement, Telix and EZAG will expand their existing collaboration to further develop access to Ga-68 supply in the United States. The parties will co-promote Illuccix[®] and GalliaPharm[®] to ensure healthcare providers nationwide have secure access to Illuccix[®] and Ga-68 generators.

Telix Americas President Dr. Bernard Lambert stated, "This important cooperation between EZAG and Telix sales teams is highly complementary to our efforts in rolling out ⁶⁸Ga-PSMA imaging across the US. Subject to FDA approval, we will together raise awareness of this state-of-the-art imaging modality and facilitate coast-to-coast access for US men living with prostate cancer."

EZAG Executive Director and responsible for the Medical segment, Dr Harald Hasselmann added, "After previously being granted distribution rights for Germany, our home market, the latest collaboration marks another important milestone for our ⁶⁸Ga generator GalliaPharm[®] and our nuclear medicine activities. We are pleased to have Telix as a partner and to be able to jointly deliver leading edge diagnostic products to prostate cancer patients in the USA."

Illuccix[®] may be prepared using a gallium-68 generator and has been validated for use with the GalliaPharm[®] generator. The Illuccix[®] New Drug Application (NDA) is currently under review by the United States Food and Drug Administration (FDA) and includes support for GalliaPharm[®].

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

Telix's lead investigational product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,¹ and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).² Telix is also progressing marketing authorisation applications for Illuccix[®] in the European Union³ and Canada.⁴ None of Telix's products have received a marketing authorisation in any jurisdiction.

¹ ASX disclosure 24/11/20.

² ASX disclosure 14/04/21.

³ ASX disclosure 1/05/20.

⁴ ASX disclosure 16/12/20.

About Eckert & Ziegler Strahlen und Medizintechnik AG

About Eckert & Ziegler Strahlen und Medizintechnik AG Eckert & Ziegler Strahlen und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. For more information visit www.ezag.com.

Telix Corporate Contact

Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
Managing Director and CEO
Email: chris.behrenbruch@telixpharma.com

Telix Corporate Communications

Dr. Stewart Holmstrom
Telix Pharmaceuticals Limited
Director of Corporate Communications
Email: stewart.holmstrom@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.